.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,387,266

« Back to Dashboard

Claims for Patent: 9,387,266

Title:Precursor compound of radioactive halogen-labeled organic compound
Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [.sup.18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: ##STR00001## wherein n is an integer of 0 or of 1 to 4; R.sup.1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by --OR.sup.2; R.sup.2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R.sup.3 is a protective group.
Inventor(s): Ito; Osamu (Chiba, JP), Hayashi; Akio (Chiba, JP), Kurosaki; Fumie (Chiba, JP), Toyama; Masahito (Chiba, JP), Shinmura; Toshiyuki (Chiba, JP), Harano; Arinori (Chiba, JP)
Assignee: NIHON MEDI-PHYSICS CO., LTD. (Tokyo, JP)
Application Number:14/814,185
Patent Claims: 1. A method of diagnosing tumors using Positron Emission Tomography, the method comprising producing 1-amino-3[.sup.18F]fluorocyclobutanecarboxylic acid from a precursor compound which is represented by the following formula (1): ##STR00003## wherein n is 0; R.sup.1 is an ethyl substituent; X is a trifluormethanesulfonate substituent; and R.sup.3 is a t-butoxy carbonyl substituent, wherein the method includes adding radioactive fluoride to the precursor compound, wherein the reaction with radioactive fluoride is carried out in acetonitrile and deprotecting the precursor compound to which radioactive fluoride has been added to produce 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid, wherein the deprotecting comprises a method in which an acid is added, wherein the method substantially does not give methanol in the production of 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid; and administering the 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid to a subject in order to carry out Positron Emission Tomography.

2. The method according to claim 1 wherein the acid is hydrochloric acid.

3. A method of diagnosing tumors using Positron Emission Tomography, the method comprising producing 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid from a precursor compound which is represented by the following formula (2): ##STR00004## wherein Et represents an ethyl substituent; TfO represents a trifluoromethanesulfonate substituent; and Boc represents a t-butoxy carbonyl substituent, wherein producing the 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid from the precursor compound includes adding radioactive fluoride to the precursor compound, wherein the reaction with radioactive fluoride is carried out in acetonitrile, and deprotecting the precursor compound to which radioactive fluoride has been added to produce 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid, wherein the deprotecting comprises a method in which hydrochloric acid is added, wherein the method substantially does not give methanol in the production of 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid; and administering the 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid to a subject in order to carry out Positron Emission Tomography.

4. A method of diagnosing tumors using Positron Emission Tomography, the method comprising producing 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid from a precursor compound which is represented by the following formula (2): ##STR00005## wherein Et represents an ethyl substituent; TfO represents a trifluoromethanesulfonate substituent; and Boc represents a t-butoxy carbonyl substituent, wherein producing the 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid from the precursor compound includes adding radioactive fluoride to the precursor compound, wherein the reaction with radioactive fluoride is carried out in acetonitrile, and deprotecting the precursor compound to which radioactive fluoride has been added to produce 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid, wherein the deprotecting comprises a method in which an acid is added, the method substantially does not give methanol in the production of 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid; and administering the 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid to a subject in order to carry out Positron Emission Tomography.

5. A method of diagnosing tumors using Positron Emission Tomography, the method comprising producing 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid from a precursor compound which is represented by the following formula (1): ##STR00006## wherein n is 0; R.sup.1 is an ethyl substituent; X is a trifluormethanesulfonate substituent; and R.sup.3 is a t-butoxy carbonyl protective group, wherein the producing comprises adding radioactive fluoride to the precursor compound, wherein the reaction with radioactive fluoride is carried out in acetonitrile, and deprotecting the precursor compound to which radioactive fluoride has been added in producing the 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid, wherein the deprotecting includes adding an acid, wherein the producing substantially does not give methanol in the production of 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid; and administering the 1-amino-3-[.sup.18F]fluorocyclobutanecarboxylic acid to a subject in order to carry out Positron Emission Tomography.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc